文献速递瓣膜外科

新型带支架牛心包主动脉生物瓣的一年结局

One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-04-18

该研究评估新型带支架牛心包主动脉瓣的安全性和有效性,纳入864例有症状中重度主动脉瓣狭窄或慢性重度主动脉瓣反流患者。主要终点为瓣膜相关不良事件线性率与FDA客观性能标准比较,死亡、血栓栓塞、血栓形成、瓣周漏和心内膜炎达标,但出血未达标。1年全因死亡和瓣膜相关死亡免除率分别为96.4%和99.7%,血流动力学改善。

要点

  • 1年全因死亡免除率96.4%,瓣膜相关死亡免除率99.7%。
  • 主要终点中出血(所有和主要)未达到FDA客观性能标准。
  • 有效瓣口面积从0.9±0.5增至1.5±0.4,平均跨瓣压差从42.7±16.5降至12.5±4.3(P<.0001)。

核心结论

  • 新型带支架牛心包主动脉瓣总体死亡率和瓣膜相关不良事件低,血流动力学性能与其他外科主动脉瓣相当。

研究设计与样本

  • 试验纳入有症状的中度或重度主动脉瓣狭窄或慢性重度主动脉瓣反流患者,评估出院时、3至6个月和1年的死亡、瓣膜相关不良事件、功能恢复和血流动力学性能。
  • 主要分析纳入864例接受植入的患者,随访904.1瓣膜年,577例完成1年评估。

主要发现

  • 主要终点在死亡、血栓栓塞、血栓形成、所有和主要瓣周漏以及心内膜炎方面达到,但在所有和主要出血方面未达到。
  • 1年全因死亡免除率为96.4%,瓣膜相关死亡免除率为99.7%。
  • 从基线至1年,纽约心脏协会(NYHA)心功能分级变化:I级从10.8%至73.7%;II级从48.9%至22.6%;III级从38.0%至3.5%;IV级从2.3%至0.2%。
  • 有效瓣口面积从0.9±0.5增加至1.5±0.4(P<.0001),平均主动脉瓣压差从42.7±16.5降低至12.5±4.3(P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study objectives were to evaluate the safety, effectiveness, and hemodynamic performance of a new stented bovine pericardial aortic valve. METHODS: This trial enrolled patients with symptomatic moderate or severe aortic stenosis or chronic, severe aortic regurgitation. We assessed death, valve-related adverse events, functional recovery, and hemodynamic performance at discharge, 3 to 6 months, and 1 year, as required by the US Food and Drug Administration for regulatory approval. The primary analysis compared late linearized rates of valve-related adverse events after implantation with Food and Drug Administration-specified objective performance criteria to determine whether the adverse event rates associated with the valve are within acceptable limits. Adverse events included thromboembolism, thrombosis, all and major hemorrhage, all and major paravalvular leak, and endocarditis. RESULTS: The primary analysis included 864 patients who received an implant and 904.1 valve-years of follow-up. A total of 577 patients completed the 1-year evaluation. The primary end point was met for death, thromboembolism, thrombosis, all and major paravalvular leak, and endocarditis, but not for all and major hemorrhage. At 1 year, freedom from all death and from valve-related death was 96.4% and 99.7%, respectively. From baseline to 1 year, New York Heart Association class changed as follows: I, 10.8% to 73.7%; II, 48.9% to 22.6%; III, 38.0% to 3.5%; and IV, 2.3% to 0.2%. Effective orifice area increased from 0.9 ± 0.5 to 1.5 ± 0.4 (P < .0001), and mean aortic gradient decreased from 42.7 ± 16.5 to 12.5 ± 4.3 (P < .0001). CONCLUSIONS: This analysis of a new stented bovine pericardial aortic valve demonstrated low overall mortality and valve-related adverse events, and hemodynamic performance comparable to that of other surgical aortic valves.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sabik JF, Rao V, Lange R, et al. One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. J Thorac Cardiovasc Surg. 2018. PMID: 29778342. doi:10.1016/j.jtcvs.2018.03.171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。